| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 105.79 mm | 105.79 mm | 105.79 mm | 105.79 mm | 105.79 mm | 105.79 mm |
| Cash burn (monthly) | 8.99 mm | 9.97 mm | 12.92 mm | 8.46 mm | 281.33 k | 2.27 mm |
| Cash used (since last report) | 45.69 mm | 50.66 mm | 65.67 mm | 43.01 mm | 1.43 mm | 11.53 mm |
| Cash remaining | 60.10 mm | 55.13 mm | 40.12 mm | 62.78 mm | 104.36 mm | 94.27 mm |
| Runway (months of cash) | 6.7 | 5.5 | 3.1 | 7.4 | 371.0 | 41.6 |
| 13F holders | Current |
|---|---|
| Total holders | 91 |
| Opened positions | 23 |
| Closed positions | 30 |
| Increased positions | 33 |
| Reduced positions | 13 |
| 13F shares | Current |
|---|---|
| Total value | 105.60 bn |
| Total shares | 43.40 mm |
| Total puts | 2.80 k |
| Total calls | 47.00 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vida Ventures | 4.78 mm | $142.98 mm |
| Vida Ventures Advisors | 4.52 mm | $16.92 bn |
| GILD Gilead Sciences | 4.13 mm | $15.43 bn |
| Westlake BioPartners Fund I | 3.79 mm | $20.15 mm |
| Bain Capital Life Sciences Investors | 3.37 mm | $12.60 bn |
| Bain Capital Life Sciences Opportunities III | 3.16 mm | $0.00 |
| Northpond Ventures III | 2.81 mm | $81.36 mm |
| JPM JPMorgan Chase & Co. | 2.17 mm | $8.10 bn |
| Novo Holdings A/S | 1.85 mm | $6.92 bn |
| BlackRock | 1.67 mm | $6.26 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Feb 25 | Christi Shaw | Stock Option Common Stock | Grant | Acquire A | No | No | 3.03 | 38,679 | 117.20 k | 38,679 |
| 22 Jan 25 | Naji Gehchan | Stock Option Common Stock | Grant | Acquire A | No | No | 3.29 | 425,000 | 1.40 mm | 425,000 |
| 21 Oct 24 | Mert Aktar | Stock Option Common Stock | Grant | Acquire A | No | No | 5.2 | 87,741 | 456.25 k | 87,741 |
